In melanoma and lymphoma patients, these cells exhibit improved persistence and synergy with indigenous CD8+ T cells when co-administered with checkpoint inhibitors (e.g., anti-PD-1) (Yesildag et al., 2018). The gene discussed is CD8A; the disease is melanoma.